Tech Company Financing Transactions

XyloCor Therapeutics Funding Round

XyloCor Therapeutics secured a $17 million Series A funding round on 12/7/2018. Backers included Life Sciences Partners, Sofinnova Ventures and private investors.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series A

Life Sciences Partners (Lead Investor)

Sofinnova Ventures (Lead Investor)

Proceeds Purpose
Proceeds from the financing will be used to advance the development of lead product candidate XC001, a cardiovascular angiogenic gene therapy, and expand the company's business and operational structure.

Company Information

Company Status
Private & Independent
Mailing Address
76 Longview Ln.
Newtown Square, PA 19073
Email Address
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. Our lead product candidate, XC001, is in clinical development for patients with refractory angina for which there are no treatment options.
XyloCor Therapeutics LinkedIn Company Profile
Social Media
XyloCor Therapeutics Company Twitter Account
Company News
XyloCor Therapeutics News
XyloCor Therapeutics on Facebook
XyloCor Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Albert Gianchetti
  Albert Gianchetti LinkedIn Profile  Albert Gianchetti Twitter Account  Albert Gianchetti News  Albert Gianchetti on Facebook
Chief Medical Officer
Rickey Reinhardt
  Rickey Reinhardt LinkedIn Profile  Rickey Reinhardt Twitter Account  Rickey Reinhardt News  Rickey Reinhardt on Facebook
VP - Finance
Michael Carson
  Michael Carson LinkedIn Profile  Michael Carson Twitter Account  Michael Carson News  Michael Carson on Facebook
VP - Manufacturing
Alexander Gaidamaka
  Alexander Gaidamaka LinkedIn Profile  Alexander Gaidamaka Twitter Account  Alexander Gaidamaka News  Alexander Gaidamaka on Facebook
VP - Operations
Dawn Byrnes
  Dawn Byrnes LinkedIn Profile  Dawn Byrnes Twitter Account  Dawn Byrnes News  Dawn Byrnes on Facebook
VP - R & D
Howard Dittrich
  Howard Dittrich LinkedIn Profile  Howard Dittrich Twitter Account  Howard Dittrich News  Howard Dittrich on Facebook



Browse more venture capital transactions:

Prev: 12/7/2018: MoEngage venture capital transaction
Next: 12/7/2018: Snapt venture capital transaction


Share this article


Where The Data Comes From

We do our best to record every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The information comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary